Phase Ib, Single-center, Randomized, Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Ferroquine (Primary) ; ZY 19489 (Primary)
- Indications Falciparum malaria; Malaria
- Focus Adverse reactions
- Acronyms ZYFER-1
- Sponsors Zydus Lifesciences
Most Recent Events
- 01 Oct 2024 Status changed from not yet recruiting to recruiting.
- 07 Jun 2024 Planned initiation date changed from 1 Apr 2024 to 1 Aug 2024.
- 08 Feb 2024 Planned End Date changed from 30 May 2024 to 30 May 2025.